Data from multiple sources - Curated by Toby Galbraith - Last updated 11 April 2017

Focus on Other Skin Disorders

Even mild skin disease can cause significant distress for patients, due to associated visibility and stigma, and this is of particular relevance for conditions which affect the face and hands. In this broad topic we cover conditions ranging in severity from life-threatening and highly disfiguring such as harlequin ichthyosis, to conditions as benign as freckles.

Read more on Other skin disorders

 

Latest news articles

Added 17 days ago Drug news

Phase IV study results for Restylane dermal fillers indicate benefits in facial expressions- Galderma

Galderma announced the results from two Phase IV clinical studies of its most recent additions to the Restylane family of...

Added 30 days ago Drug news

EU Commission approves Amgevita (biosimilar adalimumab) for all indications of the originator drug.- Amgen.

Amgen has announced that the European Commission (EC) has granted marketing authorization for Amgevita (biosimilar adalimumab) in all available indications....

Added 1 month ago Drug news

Successful Phase III trial of Ameluz (5-aminolevulinic acid) with photodynamic therapy to treat actinic keratosis.- Biofrontera AG

Biofrontera AG announced detailed results from its Phase III clinical trial evaluating the safety and efficacy of its topical prescription...

View all news articles

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

Visit Chronic Spontaneous Urticaria (CSU)

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal

Guidelines

Canadian Guidelines for the Management of Plaque Psoriasis 2009

Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases. 

Added February 2017 ago

Adalimumab for treating moderate to severe hidradenitis suppurativa

Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

Added February 2017 ago

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

In recognition of the impact of psoriasis on patients the World Health Assembly (WHA) in May 2014 supported including psoriasis into the group of non-communicable diseases.

Added February 2017 ago

View all guidelines

Journal articles

Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa.

It is challenging to estimate a true prevalence of hidradenitis suppurativa (HS) because it is underdiagnosed and misdiagnosed.

Added March 2017 ago

Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.

Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions...

Added March 2017 ago

Recognizing and managing comorbidities and complications in hidradenitis suppurativa.

The list of comorbidities associated with hidradenitis suppurativa (HS) is extensive, although these diseases do not necessarily share a common causality.

Added March 2017 ago

View all journal articles

Clinical trials

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added February 2017 ago

Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting - HARMONY Study

This study will assess the effects of adalimumab treatment in moderate to severe Hidradenitis Suppurativa (HS) patients in the real world setting.

Added July 2016 ago

Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) (SHARPS)

The objective of this study is to assess the safety and efficacy of adalimumab prior to surgery in subjects with moderate to severe Hidradenitis Suppurativa (HS) who are surgical candidates.

Added July 2016 ago

View all clinical trials
Liam Farrell

Dr Liam Farrell is from Rostrevor in Northern Ireland. He was a family doctor in Crossmaglen, Northern Ireland and a tutor in palliative care. An award-winning satirical columnist and broadcaster, his current columns include the British Medical Journal and GP. He is a member of the ... Read more

Bad smells are good

Delicacy is not a virtue in this job.

CME

Dermatological emergencies in children

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0

Malignancy and actinic disease: is this malignant?

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
15

Hidradenitis suppurativa: diagnosis and management

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
View all CME